Influence of gender on tamoxifen-induced biochemical changes in serum of rats

Molecular and Cellular Biochemistry

Volumn 301, Issue 1-2, 2007, Pages 137-142

  Hemieda, Faried Abdel Kader El Sayed ^a  

^a Mansoura University   (Egypt)

Author keywords

Cholesterol; Creatinine; Phosphatases; Rats; Serum; Tamoxifen; Transaminases; Triglycerides

Indexed keywords

ACID PHOSPHATASE; ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; CALCIUM; CHOLESTEROL; CREATININE; LIPID; TAMOXIFEN; TAMOXIFEN CITRATE;

ABNORMAL LABORATORY RESULT; ACID PHOSPHATASE BLOOD LEVEL; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD ANALYSIS; CALCIUM BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE PREDISPOSITION; DRUG MEGADOSE; ENZYME ACTIVITY; FEMALE; LIPID BLOOD LEVEL; LIVER TOXICITY; MALE; METABOLIC DISORDER; NONHUMAN; PROTEIN BLOOD LEVEL; RAT; SEX DIFFERENCE;

ACID PHOSPHATASE; ALANINE TRANSAMINASE; ANIMALS; ASPARTATE AMINOTRANSFERASES; CALCIUM; CHOLESTEROL; CREATININE; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; LIVER; MALE; RANDOM ALLOCATION; RATS; SERUM; SERUM ALBUMIN; SEX FACTORS; TAMOXIFEN;

ANIMALIA; RATTUS;

EID: 34250157053     PISSN: 03008177     EISSN: 15734919     Source Type: Journal    
DOI: 10.1007/s11010-006-9405-2     Document Type: Article

References (49)

1. Robinson E, Kimmick GG, Muss HB (1996) Tamoxifen in postmenopausal women a safety perspective. Drugs Aging 8:329-337
2. Jordan VC (1976) Antiestrogenic and antitumor properties of tamoxifen in laboratory animals. Cancer Treat Rep 60:1409-1419
3. Love RR, Newcomb PA, Wiebe DA, Surawicz TS, Jordan VC, Carbone PP, DeMets DL (1990) Effects of tamoxifen therapy on lipids and lipoprotein levels in postmenopausal patients with node-negative breast cancer. J Natl Cancer Inst 82:1327-1332
4. Floren LC, Hebert MF, Venook AP, Jordan VC, Cisneros A, Somberg KA (1998) Tamoxifen in liver disease: Potential exacerbation of hepatic dysfunction. Ann Oncol 9:1123-1126
5. Williams GM, Iatropoulos MJ, Djordjevic MV, Kaltenberg OP (1993) The triphenylethylene drug tamoxifen is a strong liver carcinogen in the rat. Carcinogenesis 14:315-317
6. Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL, Cronin WM, other NSABP contributors (1994) Endometrial cancer in tamoxifen-treated breast cancer patients: Findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 86:527-537
7. Dnistrian AM, Schwartz MK, Greenberg EJ, Smith CA, Schwartz DC (1993) Effect of tamoxifen on serum cholesterol and lipoproteins during chemohormonal therapy. Clin Chim Acta 223:43-52
8. Thangaraju M, Kumar K, Gandhirajan R, Sachdanandam P (1994) Effect of tamoxifen on plasma lipids and lipoproteins in postmenopausal women with breast cancer. Cancer 73:659-663
9. de Medina P, Payre BL, Bernad J, Bosser I, Pipy B, Silvente-Poirot S, Favre G, Faye JC, Poirot M (2004) Tamoxifen is a potent inhibitor of cholesterol esterification and prevents the formation of foam cells. J Pharmacol Exp Ther 308:1165-1173
10. Colls BM, George PM (1998) Severe hypertriglyceridaemia and hypercholes-terolaemia associated with tamoxifen use. Clin Oncol (R Coll Radiol) 10:270-271
11. Murata Y, Ogawa Y, Saibara T, Nishioka A, Fujiwara Y, Fukumoto M, Inomata T, Enzan H, Onishi S, Yoshida S (2000) Unrecognized hepatic steatosis and non-alcoholic steatohepatitis in adjuvant tamoxifen for breast cancer patients. Oncol Rep 7:1299-1304
12. Oien KA, Moffat D, Curry GW, Dickson J, Habeshaw T, Mills PR, MacSween RPM (1999) Cirrhosis with steatohepatitis after adjuvant tamoxifen. Lancet 353:36-37
13. Xu JW, Gong J, Luo JY, Dong L, Hao Z-M, Jia A, Xu GP (2002) Estrogen reduces CCL4-induced liver fibrosis in rats. World J Gastroenterol 8:883-887
14. Pinzani M, Romanelli RG, Magli S (2001) Progression of fibrosis in chronic liver diseases: Time to tally the score. J Hepatol 34:764-767
15. Yan JC, Ma JY, Pan BR, Ma LS (2001) Study of hepatitis B in China. Shi jie Hua Ren Xiao Hua Za Zhi 9:611-616
16. Hashiba M, Kasahara T, Kim SY, Shibutani S, Degawa M (2006) DNA damage and altered gene expression of enzymes for metabolism and DNA repair by tamoxifen and toremifene in the female rat liver. Cancer Sci 97:468-477
17. Reitman S, Frankel S (1957) A colorimetric method for determination of serum glutamic oxaloacetic and glutamic pyruvic transaminases. Am J Clin Pathol 28:56-63
18. Kind PRN, King EJ (1954) Estimation of plasma phosphatase by determination of hydrolysed phenol with amino-antipyrine. J Clin Pathol 7:322-326
19. Frings CS, Fendley TW, Dunn RT, Qeen CA (1972) Improved determination of total serum lipids by the sulfophosphovanillin reaction. Clin Chem 18:673-674
20. Allain CC, Poon LS, Chan CS, Richmond W, Fu PC (1974) Enzymatic determination of total serum cholesterol. Clin Chem 20:470-475
21. Bucolo G, David H (1973) Quantitative determination of serum triglycerides by the use of enzymes. Clin Chim 19:476-484
22. Doumas BT, Watson W, Biggs H (1971) Albumin standards and the measurements of serum albumin with bromocresol green. Clin Chem Acta 31:87-96
23. Gornall AC, Bardawill CJ, David MM (1949) A colorimetric method for determination of protein. J Biol Chem 177:751
24. Bartels H, Bohmer M (1971) Micro-determination of creatinine. Clin Chim Acta 32:81-85
25. Baginski ES, Marie SS, Clark WL, Zak B (1973) Direct microdetermination of serum calcium. Clin Chim Acta 46:49-54
26. El-Beshbishy HA (2005) Hepatoprotective effect of green tea (Camellia sinensis) extract against tamoxifen-induced liver injury in rats. J Biochem Mol Biol 38:563-570
27. El-Beshbishy HA (2005) The effect of dimethyl dimethoxy biphenyl dicarboxylate (DDB) against tamoxifen-induced liver injury in rats: DDB use is curative or protective. J Biochem Mol Biol 38:300-306
28. D'Mello D, Mehta D, Pereira J, Rao CV (1999) A toxicity study of simultaneous administration of tamoxifen and diazepam to female Wistar rats. Exp Toxicol Pathol 51:549-553
29. Czerny B, Juzyszyn Z, Myśliwiec Z (2003) Effects of tamoxifen and NaF on serum and hepatic enzymes. Fluoride 36:170-176
30. Subbiah MTR, Kessel B, Agrawal M, Rajan R, Abplanalp W, Rymaszewskii Z (1993) Antioxidant potential of specific estrogens on lipid peroxidation. J Clin Endocrinol Metab 77:1095-1097
31. Harada H, Pavlick KP, Hines IN, Hoffman JM, Bharwani S, Gray L, Wolf RE, Grisham MB (2001) Selected contribution: Effects of gender on reduced-size liver ischemia and reperfusion injury. J Appl Physiol 91:2816-2822
32. Lui Q-H, Li D-G, Huang X, Zong C-H, Xu Q-F, Lu H-M (2004) Suppressive effects of 17β-estradiol on hepatic fibrosis in CCl4-induced rat model. World J Gastroenterol 10:1315-1320
33. Nuwaysir EF, Dragan YP, Jefcoate CR, Jordan VC, Pitot HC (1995) Effects of tamoxifen administration on the expression of xenobiotic metabolizing enzymes in rat liver. Cancer Res 55:1780-1786
34. Davis W, Hewer A, Rajkowski KM, Meinl W, Glatt H, Phillips DH (2000) Sex differences in the activation of tamoxifen to DNA binding species in rat liver in vivo and in rat hepatocytes in vitro: Role of sulfotransferase induction. Cancer Res 60:2887-2891
35. Dehal SS, Kupfer D (1999) Cytochrome P-450 3A and 2D6 catalyze ortho hydroxylation of 4-hydroxytamoxifen and 3-hydroxytamoxifen (droloxifene) yielding tamoxifen catechol: Involvement of catechols in covalent binding to hepatic proteins. Drug Metab Dispos 27:681-688
36. Brown AP, Morrissey RL, Crowell JA, Levine BS (1999) Difluoromethylornithine in combination with tamoxifen in female rats: -13 week oral toxicity study. Cancer Chemother Pharmacol 44:475-483
37. Thangaraju M, Rameshbabu J, Vasavi H, Hanchezhian S, Vinitha R, Sachdanandam P (1998) The salubrious effect of tamoxifen on serum marker enzymes, glycoproteins, and lysosomal enzymes levels in breast cancer women. Mol Cell Biochem 185:85-94
38. Altan N, Chen Y, Schindler M, Simon SM (1999) Tamoxifen inhibits acidification in cells independent of the estrogen receptor. Proc Natl Acad Sci USA (Cell Biology) 96:4432-4437
39. Gold E, Stapley S, Goulding A (1994) Tamoxifen and norethisterone: effects on plasma cholesterol and total body calcium content in the estrogen-deficient rat. Horm Metab Res 26:100-103
40. Kenny AM, Prestwood KM, Pilbeam CC, Raisz LG (1995) The short term effects of tamoxifen on bone turnover in older women. J Clin Endocrinol Metab 80:3287-3291
41. Reckless J, Metcalfe JC, Grainger DJ (1997) Tamoxifen decreases cholesterol sevenfold and abolishes lipid lesion development in apolipoprotein E knockout mice. Circulation 95:1542-1548
42. Wade GN, Heller HW (1993) Tamoxifen mimics the effects of estradiol on food intake, body weight and body composition in rats. Am J Physiol 264:R1392-R1398
43. Vinitha R, Thangaraju M, Sachdanandam P (1997) Effect of tamoxifen on lipids and lipid metabolising marker enzymes in experimental atherosclerosis in Wistar rats. Mol Cell Biochem 168:13-19
44. Ickenstein LM, Bandiera SM (2002) Persistent suppression of hepatic CYP2A1 expression and serum triiodothyronine levels by tamoxifen in intact female rats: Dose-response analysis and comparison with 4-hydroxytamoxifen, fulvestrant (ICI 182,780), and 17β-estradiol-3-benzoate. J Pharmacol Exp Ther 302:584-593
45. Hozumi Y, Hakamata Y, Nagai H (2005) Plasma leptin concentration in tamoxifen-treated ovariectomized rats. Gynecol Obstet Invest 59:70-74
46. Li D, Dragan Y, Jordan VC, Wang M, Pitot HC (1997) Effects of chronic administration of tamoxifen and toremifene on DNA adducts in rat liver, kidney, and uterus. Cancer Res 57:1438-1441
47. Schild LJ, Divi RL, Beland FA, Churchwell MI, Doerge DR, Gamboa da Costa G, Marques MM, Poirier MC (2003) Formation of tamoxifen-DNA adducts in multiple organs of adult female cynomolgus monkeys dosed with tamoxifen for 30 days. Cancer Res 63:5999-6003
48. Kang D-H, Yu ES, Yoon K, Johnson R (2004) The impact of gender on progression of renal disease - Potential role of estrogen-mediated vascular endothelial growth factor regulation and vascular protection. Am J Pathol 164:679-688
49. Stringer KD, Komers R, Osman SA, Oyama TT, Lindsley JN, Anderson S (2005) Gender hormones and the progression of experimental polycystic kidney disease. Kidney Int 68:1729-1739